scispace - formally typeset
W

William Flesher

Researcher at University of Rochester

Publications -  6
Citations -  729

William Flesher is an academic researcher from University of Rochester. The author has contributed to research in topics: Poison control & Medicine. The author has an hindex of 4, co-authored 4 publications receiving 598 citations. Previous affiliations of William Flesher include University of Rochester Medical Center.

Papers
More filters
Journal ArticleDOI

Mild traumatic brain injury in the United States, 1998-2000

TL;DR: The national burden of mTBI is significant and the incidence higher than that reported by others, underscoring the need to promote prevention programmes on a national level.
Journal ArticleDOI

Ethnic and racial disparities in emergency department care for mild traumatic brain injury.

TL;DR: There are significant racial and ethnic but not gender disparities in ED care for mTBI, and the causes and the relationship between these disparities and post-mTBI outcome need to be examined.
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.
Journal ArticleDOI

Lateral automobile impacts and the risk of traumatic brain injury.

TL;DR: Lateral impact is an important independent risk factor for the development of traumatic brain injury after a serious motor vehicle crash and vehicle modifications that increase head protection could reduce crash-related severe traumatic brain injuries by up to 61% and prevent up to 2,230 fatal or critical traumatic head injuries each year in the United States.
Journal ArticleDOI

Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy

TL;DR: PC is an effective alternative to the more traditional PG for treatment of febrile neutropenic hosts who have not been given prophylactic quinolones, and may decrease the necessity of additional antimicrobial agents such as amphotericin B.